Tekmira Pharmaceuticals
| Industry | Pharmaceuticals |
|---|---|
| Headquarters | Canada |
| Website |
www |
Tekmira Pharmaceuticals is a Canadian company that is developing an experimental Ebola treatment.
TKM-Ebola
The treatment TKM-Ebola was being developed under a $140 million US Department of Defence contract. TKM-Ebola began phase-1 human trials before January 14 2014 with at least three human subjects infected,[1] in July 2014 the US regulatory body placed it on hold due to safety concerns.[2]
2014 outbreak
During the 2014 ebola outbreak their stock price rose significantly.[2]
References
- ↑
- 1 2 Atkins, Richard (9 August 2014). "Biotech Stock in Spotlight: As the World Awaits Ebola Treatment, Tekmira Pharma In Prime Focus". TechNews. Retrieved 10 August 2014.
This article is issued from Wikipedia - version of the Tuesday, June 23, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.